Identification

Name
Promazine
Accession Number
DB00420  (APRD00358)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States.

Structure
Thumb
Synonyms
  • 10-(3-(Dimethylamino)propyl)phenothiazine
  • Frenil
  • N-(3-Dimethylaminopropyl)phenothiazine
  • N-Dimethylamino-1-methylethyl thiodiphenylamine
  • N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine
  • Promazin
  • Promazina
  • Promazine
  • Promazinum
External IDs
A 145 / RP 3276 / Wy 1094
Product Ingredients
IngredientUNIICASInChI Key
Promazine HydrochlorideU16EOR79U453-60-1JIVSXRLRGOICGA-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Promazine HCl Inj 50mg/mlLiquid50 mgIntramuscular; IntravenousAbbott1981-12-312008-06-06Canada
International/Other Brands
Combelen / Prazine (Pliva) / Sparine / Talofen (Abbott)
Categories
UNII
O9M39HTM5W
CAS number
58-40-2
Weight
Average: 284.419
Monoisotopic: 284.13471934
Chemical Formula
C17H20N2S
InChI Key
ZGUGWUXLJSTTMA-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
IUPAC Name
dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12

Pharmacology

Indication

Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.

Pharmacodynamics

Promazine belongs to a group of medications known as the phenothiazine antipsychotics. It acts by blocking a variety of receptors in the brain, particularly dopamine receptors. Dopamine is involved in transmitting signals between brain cells. When there is an excess amount of dopamine in the brain it causes over-stimulation of dopamine receptors. These receptors normally act to modify behaviour and over-stimulation may result in psychotic illness. Promazine hydrochloride blocks these receptors and stops them becoming over-stimulated, thereby helping to control psychotic illness. Promazine has weak extrapyramidal and autonomic side effects which lead to its use in the elderly, for restless or psychotic patients. Its anti-psychotic effect is also weaker and it is not useful in general psychiatry.

Mechanism of action

Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption

Absorption may be erratic and peak plasma concentrations show large interindividual differences.

Volume of distribution
Not Available
Protein binding

94%

Metabolism

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetaminePromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetaminePromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Promazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Promazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Promazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Promazine can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
AcepromazinePromazine may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Promazine.Approved
Acetyl sulfisoxazoleThe metabolism of Promazine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Promazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Promazine is combined with Adipiplon.Investigational
AdrafinilPromazine may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatinePromazine may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Promazine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Promazine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Promazine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Promazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Promazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Promazine.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Promazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Promazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Promazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmantadineThe therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine.Approved
AmibegronPromazine may decrease the vasoconstricting activities of Amibegron.Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Promazine.Approved, Withdrawn
AmiodaronePromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulpridePromazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazPromazine may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylinePromazine may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Promazine is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Promazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapinePromazine may increase the antihypertensive activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Promazine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Promazine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Promazine.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Promazine is combined with Amrinone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Promazine.Approved, Investigational
AnagrelidePromazine may increase the QTc-prolonging activities of Anagrelide.Approved
AnisodaminePromazine may decrease the vasoconstricting activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Promazine.Approved, Investigational
ApalutamideThe serum concentration of Promazine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe therapeutic efficacy of Promazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApraclonidinePromazine may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Promazine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Promazine.Approved
AranidipineThe risk or severity of hypotension can be increased when Promazine is combined with Aranidipine.Approved, Investigational
ArbutaminePromazine may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Promazine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.Approved, Investigational
ArmodafinilThe metabolism of Promazine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Promazine.Investigational
Arsenic trioxidePromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPromazine may increase the QTc-prolonging activities of Artemether.Approved
ArtemisininThe serum concentration of Promazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Promazine can be increased when it is combined with Artemotil.Approved
ArtenimolThe serum concentration of Promazine can be increased when it is combined with Artenimol.Approved, Investigational
ArtesunateThe serum concentration of Promazine can be increased when it is combined with Artesunate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Promazine is combined with Articaine.Approved
AsenapinePromazine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Promazine.Approved, Withdrawn
AsunaprevirThe metabolism of Asunaprevir can be decreased when combined with Promazine.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Promazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Promazine.Approved
AtomoxetineThe metabolism of Promazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Promazine can be increased when it is combined with Atovaquone.Approved
AvanafilAvanafil may increase the hypotensive activities of Promazine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Azaperone.Investigational, Vet Approved
AzelastinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Promazine is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Promazine is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Promazine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Promazine is combined with Baclofen.Approved
BambuterolPromazine may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Promazine is combined with Barnidipine.Approved
BedaquilinePromazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Promazine.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Promazine is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Promazine is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Promazine is combined with Benperidol.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Promazine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Benzocaine.Approved, Investigational
BenzphetaminePromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Promazine.Approved
Benzylpenicilloyl PolylysinePromazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Promazine.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Promazine.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
BevantololPromazine may increase the antihypertensive activities of Bevantolol.Approved
BezitramidePromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinThe risk or severity of hypotension can be increased when Promazine is combined with Bioallethrin.Approved, Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Promazine.Approved
BitolterolPromazine may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe metabolism of Promazine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Promazine.Approved
BortezomibThe metabolism of Promazine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Promazine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Promazine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Promazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Promazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Promazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Promazine.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Promazine.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Promazine.Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Promazine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Promazine.Approved
BuprenorphinePromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Promazine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Promazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Promazine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Promazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Promazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promazine.Approved
CaffeineThe metabolism of Promazine can be decreased when combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Promazine is combined with Canertinib.Investigational
CapecitabineThe metabolism of Promazine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Promazine.Approved
CarbamazepineThe metabolism of Promazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Promazine is combined with Carboxyamidotriazole.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Promazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.Approved
CaroverineThe risk or severity of hypotension can be increased when Promazine is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Promazine.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Promazine.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Promazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Promazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Promazine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Promazine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.Approved
ChloroquinePromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Promazine.Approved
ChlorphenterminePromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproguanilThe serum concentration of Promazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazinePromazine may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Promazine.Approved
CholecalciferolThe metabolism of Promazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe risk or severity of hypotension can be increased when Promazine is combined with Cilnidipine.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Promazine.Approved, Investigational
CimetidineThe metabolism of Promazine can be decreased when combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Promazine.Approved, Investigational
CiprofloxacinPromazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolinePromazine may decrease the vasoconstricting activities of Cirazoline.Experimental
CisapridePromazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramPromazine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Promazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Promazine can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolPromazine may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Promazine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Promazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Promazine is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Promazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Promazine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Promazine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Promazine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Promazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePromazine may increase the antihypertensive activities of Clozapine.Approved
CobicistatThe metabolism of Promazine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Promazine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Promazine.Approved, Investigational
CrisaboroleThe metabolism of Promazine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibPromazine may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe metabolism of Promazine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Promazine is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.Approved
Cycloguanil embonateThe serum concentration of Promazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Promazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Promazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Promazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Promazine.Approved
DapiprazoleDapiprazole may increase the antihypertensive activities of Promazine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Promazine.Investigational
DapsoneThe serum concentration of Promazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Promazine.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Promazine is combined with Darodipine.Experimental
DarunavirThe metabolism of Promazine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Promazine.Approved
DasatinibThe serum concentration of Promazine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Promazine.Approved, Investigational
DeferasiroxThe serum concentration of Promazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Promazine.Approved
DelavirdineThe metabolism of Promazine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Promazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Desflurane.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Promazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Promazine is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Promazine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Promazine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Promazine.Approved, Investigational
DextroamphetaminePromazine may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Promazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Promazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Promazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Promazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Promazine is combined with Diethyl ether.Experimental
DiethylpropionPromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Promazine.Approved, Illicit
DihydroergotamineThe metabolism of Promazine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Promazine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Promazine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Promazine is combined with Diphenoxylate.Approved, Illicit
DipivefrinPromazine may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Promazine.Approved
DisopyramidePromazine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dixyrazine.Experimental
DL-MethylephedrinePromazine may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutaminePromazine may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilidePromazine may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronPromazine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidonePromazine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Promazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Promazine.Approved
DopexaminePromazine may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Promazine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Promazine can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Promazine is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Promazine.Approved
DoxepinPromazine may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllinePromazine may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Promazine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Promazine.Approved, Investigational
DoxycyclineThe serum concentration of Promazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Promazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Illicit
DronedaronePromazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Promazine is combined with Drotebanol.Experimental, Illicit
DroxidopaPromazine may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Promazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Promazine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Promazine is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Promazine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Promazine is combined with Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Promazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Promazine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Promazine is combined with Eltanolone.Investigational
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Promazine.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Promazine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Promazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Promazine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Promazine.Experimental
EperisoneThe risk or severity of hypotension can be increased when Promazine is combined with Eperisone.Approved, Investigational
EphedraPromazine may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrinePromazine may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Promazine.Approved, Investigational
EpinephrinePromazine may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promazine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Promazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Promazine.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Promazine.Experimental
EscitalopramPromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Promazine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Promazine.Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Promazine.Approved
EsomeprazoleThe metabolism of Promazine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.Approved, Investigational
EtafedrinePromazine may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolPromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Promazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Promazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Promazine is combined with Etifoxine.Investigational, Withdrawn
EtilefrinePromazine may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Promazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Promazine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Promazine can be decreased when combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Promazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Promazine.Approved
FelodipineThe risk or severity of hypotension can be increased when Promazine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Promazine is combined with Fendiline.Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Promazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoterolPromazine may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Promazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promazine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Promazine is combined with Fexofenadine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Promazine.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Promazine is combined with Fish oil.Approved, Nutraceutical
FlecainidePromazine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.Approved, Investigational
FloxuridineThe metabolism of Promazine can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Promazine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Promazine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Promazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Promazine can be decreased when combined with Fluorouracil.Approved
FluoxetinePromazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPromazine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Promazine.Approved
FluvoxamineThe metabolism of Promazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Promazine.Approved, Investigational
FosamprenavirThe metabolism of Promazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Promazine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Promazine.Approved
FosphenytoinThe metabolism of Promazine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Promazine is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Promazine.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Promazine.Approved, Investigational
Fusidic AcidThe serum concentration of Promazine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidPromazine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Promazine.Approved
GallopamilThe risk or severity of hypotension can be increased when Promazine is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Promazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Promazine.Approved, Investigational
GemfibrozilThe metabolism of Promazine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrinePromazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Promazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Promazine is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Promazine.Approved
GranisetronPromazine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzPromazine may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Promazine can be increased when it is combined with Halofantrine.Approved
HaloperidolPromazine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Promazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Promazine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.Approved
HexoprenalinePromazine may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenaminePromazine may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Promazine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promazine.Approved, Investigational
HydrocodonePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Promazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetaminePromazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe serum concentration of Promazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Promazine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Promazine.Approved
IbutilidePromazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Promazine.Approved
IdelalisibThe metabolism of Promazine can be decreased when combined with Idelalisib.Approved
IloperidonePromazine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Promazine can be decreased when combined with Imatinib.Approved
ImipraminePromazine may increase the antihypertensive activities of Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Promazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Promazine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Promazine.Withdrawn
IndinavirThe metabolism of Promazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Promazine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Promazine.Withdrawn
Iofetamine I-123Promazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Promazine.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.Approved
IrbesartanThe metabolism of Promazine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Promazine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Promazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Promazine can be increased when used in combination with Isocarboxazid.Approved
IsoetarinePromazine may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Isoflurane.Approved, Vet Approved
IsometheptenePromazine may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Promazine can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalinePromazine may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprinePromazine may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Promazine can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Promazine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Promazine.Approved
IvacaftorThe serum concentration of Promazine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Promazine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Promazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Promazine.Approved
LacidipineThe risk or severity of hypotension can be increased when Promazine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Promazine.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
LeflunomideThe metabolism of Promazine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibPromazine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Promazine is combined with Lercanidipine.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Promazine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Promazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
LevobunololPromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Promazine can be decreased when used in combination with Levodopa.Approved
LevofloxacinPromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Promazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Promazine.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Promazine is combined with Levorphanol.Approved
LevosalbutamolPromazine may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe metabolism of Promazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Promazine is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Promazine.Approved, Investigational
LisdexamfetaminePromazine may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Promazine.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Promazine.Experimental
LobeglitazoneThe metabolism of Promazine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Promazine can be increased when used in combination with Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Promazine.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Promazine.Approved
LopinavirPromazine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Loprazolam.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Promazine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Promazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Promazine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Promazine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Promazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.Approved
LuliconazoleThe serum concentration of Promazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Promazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePromazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe therapeutic efficacy of Promazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Promazine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Promazine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Promazine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Promazine can be increased when it is combined with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Promazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Promazine is combined with Menthol.Approved
MephedronePromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePromazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Promazine.Investigational, Withdrawn
MepindololMepindolol may increase the orthostatic hypotensive activities of Promazine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Promazine is combined with Meptazinol.Experimental
MequitazinePromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.Approved, Investigational
MetaraminolPromazine may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Promazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Promazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Promazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Promazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.Approved
MethotrimeprazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxaminePromazine may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
MethoxyphenaminePromazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.Approved
MethyldopaPromazine may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Promazine is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Promazine.Approved, Illicit, Withdrawn
MetipranololPromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.Approved, Investigational
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Promazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Promazine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Promazine.Approved
MetyrosinePromazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Promazine can be decreased when combined with Mexiletine.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Promazine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Promazine is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.Approved, Illicit
MidodrinePromazine may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetaminePromazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Promazine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Promazine.Approved, Investigational
MifepristoneThe serum concentration of Promazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Promazine is combined with Milnacipran.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Promazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Promazine.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Promazine.Investigational
MirtazapinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Promazine can be decreased when it is combined with Mitotane.Approved
MizoribineThe serum concentration of Promazine can be increased when it is combined with Mizoribine.Investigational
MMDAPromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Promazine.Approved, Investigational
ModafinilThe metabolism of Promazine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Promazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Promazine is combined with Molindone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Promazine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
MoxonidinePromazine may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Promazine.Approved
NaftopidilThe risk or severity of hypotension can be increased when Promazine is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Promazine is combined with Nalbuphine.Approved
NaphazolinePromazine may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Promazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Promazine.Approved, Investigational
NefazodonePromazine may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Promazine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Promazine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Promazine can be increased when combined with Nevirapine.Approved
NicardipinePromazine may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the antihypertensive activities of Promazine.Approved, Investigational
NicomorphinePromazine may increase the hypotensive activities of Nicomorphine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Promazine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Promazine.Approved
NiguldipinePromazine may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibPromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Promazine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Promazine is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Promazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Promazine is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Promazine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of hypotension can be increased when Promazine is combined with Nitrendipine.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrous oxide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Nordazepam.Approved
NorepinephrinePromazine may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrinePromazine may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Promazine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Promazine is combined with Normethadone.Approved, Illicit
NortriptylinePromazine may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinPromazine may decrease the vasoconstricting activities of Nylidrin.Approved
OctopaminePromazine may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Promazine.Approved, Investigational
OfloxacinPromazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapinePromazine may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Promazine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Promazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Promazine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPromazine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Promazine is combined with Opium.Approved, Illicit
OrciprenalinePromazine may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrinePromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Promazine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Promazine is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Promazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Promazine.Approved, Illicit, Investigational
OxyfedrinePromazine may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolinePromazine may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PalbociclibThe serum concentration of Promazine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePromazine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Promazine.Approved, Investigational
PanobinostatPromazine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Promazine can be decreased when combined with Pantoprazole.Approved
ParaldehydePromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Promazine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Promazine.Approved
PazopanibPromazine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Promazine is combined with Penfluridol.Experimental
PentamidinePromazine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Promazine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Promazine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Promazine is combined with Perazine.Approved, Investigational
PerflutrenPromazine may increase the QTc-prolonging activities of Perflutren.Approved
PergolidePromazine may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Promazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Promazine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Promazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Promazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Promazine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Promazine is combined with Phenazocine.Experimental
PhendimetrazinePromazine may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Promazine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Promazine is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Promazine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Promazine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Promazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Promazine is combined with Phenoxyethanol.Approved
PhenterminePromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePromazine may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrinePromazine may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolaminePromazine may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Promazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozidePromazine may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Promazine is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.Approved, Investigational
PiperaquineThe serum concentration of Promazine can be increased when it is combined with Piperaquine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Promazine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Promazine.Approved, Investigational
PirbuterolPromazine may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Promazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Promazine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Promazine.Approved, Investigational
PizotifenPromazine may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Promazine.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Promazine.Approved, Investigational
PosaconazoleThe metabolism of Promazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Promazine.Approved
PramipexolePromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Promazine.Approved
PregabalinThe therapeutic efficacy of Promazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolPromazine may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Promazine is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Prilocaine.Approved
PrimaquinePromazine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Promazine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePromazine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Promazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Promazine.Approved, Investigational
ProcaterolPromazine may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Promazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Promazine.Approved, Vet Approved
ProguanilThe serum concentration of Promazine can be increased when it is combined with Proguanil.Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Promazine.Approved, Investigational
PropafenoneThe serum concentration of Promazine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Promazine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.Approved, Vet Approved
PropericiazinePromazine may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePromazine may increase the antihypertensive activities of Propiomazine.Approved
PropiverinePromazine may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Promazine is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Promazine.Approved, Investigational
ProtokylolPromazine may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Promazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Promazine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Promazine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Promazine.Approved
PyrimethamineThe serum concentration of Promazine can be increased when it is combined with Pyrimethamine.Approved, Investigational, Vet Approved
PyronaridineThe serum concentration of Promazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.Approved, Illicit
QuetiapinePromazine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Promazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Promazine.Approved, Investigational
QuinidinePromazine may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuininePromazine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Quinisocaine.Experimental
RacepinephrinePromazine may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Promazine is combined with Raclopride.Investigational
RactopaminePromazine may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RadicicolThe serum concentration of Promazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Promazine.Approved
RanolazineThe metabolism of Promazine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Promazine.Approved, Withdrawn
RepinotanThe metabolism of Repinotan can be decreased when combined with Promazine.Investigational
ReproterolPromazine may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.Approved, Investigational
RifabutinThe metabolism of Promazine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Promazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Promazine can be increased when combined with Rifapentine.Approved, Investigational
RilmenidinePromazine may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Promazine.Approved
RimiterolPromazine may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidonePromazine may increase the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Promazine is combined with Ritanserin.Investigational
RitobegronPromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitodrinePromazine may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Promazine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Promazine is combined with Romifidine.Vet Approved
RopinirolePromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Promazine.Approved
RotigotinePromazine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Promazine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Promazine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Promazine.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Promazine.Approved
SaquinavirThe metabolism of Promazine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Promazine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Promazine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Promazine is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Promazine is combined with Sepranolone.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Promazine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Promazine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Promazine.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Promazine.Approved
SiltuximabThe serum concentration of Promazine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Promazine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Promazine.Approved
SinefunginThe serum concentration of Promazine can be increased when it is combined with Sinefungin.Experimental
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
SolabegronPromazine may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Promazine.Approved
SorafenibThe metabolism of Promazine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPromazine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Promazine.Experimental
St. John's WortThe serum concentration of Promazine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Promazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Promazine can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadoxineThe serum concentration of Promazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfamethoxazoleThe metabolism of Promazine can be decreased when combined with Sulfamethoxazole.Approved
SulfametopyrazineThe serum concentration of Promazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleThe metabolism of Promazine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpiridePromazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Promazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Promazine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
SuvorexantPromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrinePromazine may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Promazine.Approved, Investigational
TafenoquineThe serum concentration of Promazine can be increased when it is combined with Tafenoquine.Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Promazine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Promazine resulting in a loss in efficacy.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Promazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Promazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Promazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Promazine.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Promazine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinPromazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Promazine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.Approved, Investigational
Tenofovir disoproxilThe metabolism of Promazine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Promazine.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Promazine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Promazine.Approved, Withdrawn
TeriflunomideThe serum concentration of Promazine can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Promazine is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Promazine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Promazine.Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrodotoxin.Investigational
TetryzolinePromazine may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomidePromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Promazine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.Approved, Vet Approved
ThioproperazinePromazine may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Promazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Promazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Promazine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Promazine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Promazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Promazine is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Promazine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Promazine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Promazine.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
TocilizumabThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the antihypertensive activities of Promazine.Approved, Vet Approved
TolbutamideThe metabolism of Promazine can be decreased when combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Promazine is combined with Tolfenamic Acid.Approved, Investigational
TolterodineThe metabolism of Tolterodine can be decreased when combined with Promazine.Approved, Investigational
TopiramateThe metabolism of Promazine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Promazine can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifenePromazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Promazine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Promazine is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.Approved, Investigational
TrazodonePromazine may increase the antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Promazine.Approved, Investigational
TretoquinolPromazine may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Promazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Promazine is combined with Trichloroethylene.Approved
TrifluoperazinePromazine may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Promazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Promazine.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Promazine is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Promazine is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Promazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipraminePromazine may increase the antihypertensive activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
TromethamineTromethamine can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TulobuterolPromazine may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Promazine.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Promazine.Approved
UrapidilUrapidil may increase the antihypertensive activities of Promazine.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Promazine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Promazine is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Promazine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibPromazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the hypotensive activities of Promazine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Promazine.Approved
VenlafaxineThe metabolism of Promazine can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Promazine is combined with Veralipride.Experimental
VerapamilPromazine may increase the antihypertensive activities of Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Promazine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Promazine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Promazine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Promazine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Promazine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Promazine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Promazine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Promazine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Promazine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Promazine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Promazine.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Promazine is combined with WIN 55212-2.Experimental
XamoterolPromazine may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Promazine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Promazine is combined with Xylazine.Vet Approved
XylometazolinePromazine may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Promazine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Promazine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.Withdrawn
ZiprasidonePromazine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promazine.Approved, Investigational
ZolpidemPromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Promazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Promazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Promazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Promazine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolPromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US2519886
General References
  1. Cubala WJ, Jakuszkowiak-Wojten K, Burkiewicz A, Wronska A: Promazine in the treatment of delusional parasitosis. Psychiatr Danub. 2011 Jun;23(2):198-9. [PubMed:21685861]
External Links
Human Metabolome Database
HMDB0014564
KEGG Drug
D08430
KEGG Compound
C07379
PubChem Compound
4926
PubChem Substance
46504504
ChemSpider
4757
BindingDB
67545
ChEBI
8459
ChEMBL
CHEMBL564
Therapeutic Targets Database
DAP000430
PharmGKB
PA451126
HET
P2Z
Wikipedia
Promazine
ATC Codes
N05AA03 — Promazine
PDB Entries
4ma7
MSDS
Download (75.4 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Apothecon sub bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Bristol myers squibb co
Packagers
  • Baxter International Inc.
  • Liberty Pharmaceuticals
  • Prescript Pharmaceuticals
  • Primedics Laboratories
  • Sandoz
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous50 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
Chlorpromazine 200 mg tablet1.05USD tablet
Chlorpromazine Hcl 25 mg/ml0.88USD ml
Chlorpromazine 100 mg tablet0.39USD tablet
Novo-Chlorpromazine 100 mg Tablet0.35USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Novo-Chlorpromazine 50 mg Tablet0.21USD tablet
Novo-Chlorpromazine 25 mg Tablet0.18USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)203-210 °C at 3.00E-01 mm HgPhysProp
water solubility14.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.55HANSCH,C ET AL. (1995)
logS-4.3ADME Research, USCD
pKa9.36SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0207 mg/mLALOGPS
logP4.63ALOGPS
logP3.93ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.95 m3·mol-1ChemAxon
Polarizability32.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9718
Blood Brain Barrier+0.987
Caco-2 permeable+0.8813
P-glycoprotein substrateSubstrate0.7933
P-glycoprotein inhibitor IInhibitor0.6857
P-glycoprotein inhibitor IIInhibitor0.6352
Renal organic cation transporterInhibitor0.7561
CYP450 2C9 substrateNon-substrate0.7526
CYP450 2D6 substrateSubstrate0.9334
CYP450 3A4 substrateSubstrate0.5578
CYP450 1A2 substrateInhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.9483
CYP450 2D6 inhibitorInhibitor0.9622
CYP450 2C19 inhibitorNon-inhibitor0.798
CYP450 3A4 inhibitorNon-inhibitor0.9166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6784
Ames testNon AMES toxic0.9176
CarcinogenicityNon-carcinogens0.9545
BiodegradationNot ready biodegradable0.9921
Rat acute toxicity2.9416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9662
hERG inhibition (predictor II)Inhibitor0.7828
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.05 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4r-9230000000-62cbfd979fa705bc6b5e
GC-MS Spectrum - EI-BGC-MSsplash10-053i-9470000000-c8ea76fcc1b124b82db0
GC-MS Spectrum - CI-BGC-MSsplash10-000i-2090000000-c38077fbc5880feb7eab
Mass Spectrum (Electron Ionization)MSsplash10-0a4i-9430000000-708a7cbef8d61ce76846
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amine (CHEBI:8459)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A: Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 2000 Sep 25;96(1):41-50. [PubMed:10980325]
  4. Govitrapong P, Mukda S, Turakitwanakan W, Dumrongphol H, Chindaduangratn C, Sanvarinda Y: Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem Int. 2002 Oct;41(4):209-16. [PubMed:12106771]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Details
13. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:29